CN100443116C - 治疗或预防肺炎球菌感染的组合物及其用途 - Google Patents

治疗或预防肺炎球菌感染的组合物及其用途 Download PDF

Info

Publication number
CN100443116C
CN100443116C CNB2003801027586A CN200380102758A CN100443116C CN 100443116 C CN100443116 C CN 100443116C CN B2003801027586 A CNB2003801027586 A CN B2003801027586A CN 200380102758 A CN200380102758 A CN 200380102758A CN 100443116 C CN100443116 C CN 100443116C
Authority
CN
China
Prior art keywords
polypeptide
seq
streptococcus pneumoniae
immunoreation
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2003801027586A
Other languages
English (en)
Chinese (zh)
Other versions
CN1711105A (zh
Inventor
麦可·C·陈
邱创究
李忠明
陈东圣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synergy America Inc
Original Assignee
Synergy America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergy America Inc filed Critical Synergy America Inc
Publication of CN1711105A publication Critical patent/CN1711105A/zh
Application granted granted Critical
Publication of CN100443116C publication Critical patent/CN100443116C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB2003801027586A 2002-11-07 2003-11-06 治疗或预防肺炎球菌感染的组合物及其用途 Expired - Lifetime CN100443116C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42449702P 2002-11-07 2002-11-07
US60/424,497 2002-11-07

Publications (2)

Publication Number Publication Date
CN1711105A CN1711105A (zh) 2005-12-21
CN100443116C true CN100443116C (zh) 2008-12-17

Family

ID=32312819

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801027586A Expired - Lifetime CN100443116C (zh) 2002-11-07 2003-11-06 治疗或预防肺炎球菌感染的组合物及其用途

Country Status (10)

Country Link
US (2) US7217791B2 (enExample)
EP (1) EP1558280B1 (enExample)
JP (3) JP2006506989A (enExample)
KR (1) KR20050086427A (enExample)
CN (1) CN100443116C (enExample)
AU (1) AU2003291365B2 (enExample)
CA (1) CA2504938C (enExample)
ES (1) ES2451620T3 (enExample)
TW (1) TWI315986B (enExample)
WO (1) WO2004043376A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2683748C (en) 2007-04-13 2016-02-16 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP3165531B1 (en) 2010-03-12 2020-11-25 Children's Medical Center Corporation Immunogenic composition, vaccine, and uses thereof
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US9034322B2 (en) * 2011-04-21 2015-05-19 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
WO2013052643A1 (en) * 2011-10-05 2013-04-11 The Rockefeller University Dimeric bacteriophage lysins
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
US12616744B2 (en) 2014-01-21 2026-05-05 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
ES2993430T3 (en) 2014-11-21 2024-12-30 Univ Oklahoma Pneumolysin mutants and methods of use thereof
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
BR112020004509A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006951A1 (en) * 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
WO1999003884A2 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6342224B1 (en) * 1997-08-22 2002-01-29 Smithkline Beecham Biologicals, S.A. Recombinant papillomavirus vaccine and method for production and treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687688A1 (en) * 1993-12-17 1995-12-20 Universidad De Oviedo Antibodies against pneumolysine and their applications
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
EP1100921B1 (en) * 1998-07-27 2007-05-02 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
EP1980617A1 (en) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
ATE319833T1 (de) * 1999-12-17 2006-03-15 Wyeth Corp Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006951A1 (en) * 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
WO1999003884A2 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6342224B1 (en) * 1997-08-22 2002-01-29 Smithkline Beecham Biologicals, S.A. Recombinant papillomavirus vaccine and method for production and treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
immunization with plasmid expressing pneumococcalsurfaceprotein A(PspA) can elicit protection against fatalinfectionwith stretococcus pneumoniae. MCDANIEL et al.gene therapy,Vol.4 No.4. 1997 *
重组肺炎球菌溶血素的特性及其作为18C型肺炎球菌偶联菌苗的蛋白载体 . 徐犇，蒋玖.国外医学.预防.诊断.治疗用生物制品分册,，第2期. 1996 *

Also Published As

Publication number Publication date
JP2012139221A (ja) 2012-07-26
US7217791B2 (en) 2007-05-15
CN1711105A (zh) 2005-12-21
US20040213803A1 (en) 2004-10-28
KR20050086427A (ko) 2005-08-30
AU2003291365A1 (en) 2004-06-03
JP2010057501A (ja) 2010-03-18
EP1558280A2 (en) 2005-08-03
JP2006506989A (ja) 2006-03-02
WO2004043376A3 (en) 2004-10-14
EP1558280B1 (en) 2014-01-08
WO2004043376A2 (en) 2004-05-27
US20080199952A1 (en) 2008-08-21
ES2451620T3 (es) 2014-03-28
TWI315986B (en) 2009-10-21
CA2504938C (en) 2011-10-11
AU2003291365B2 (en) 2009-06-11
HK1074005A1 (en) 2005-10-28
EP1558280A4 (en) 2007-08-29
US7585669B2 (en) 2009-09-08
TW200418502A (en) 2004-10-01
CA2504938A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
US7585669B2 (en) Compositions and methods for treating or preventing pneumococcal infection
AU2018201768B2 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
KR100619350B1 (ko) 변형 면역성 뉴멀리신 백신조성물
JP4848552B2 (ja) 変異型ニューモリシンタンパク質
US9056912B2 (en) Immunogenic compositions for Streptococcus pyogenes
EP2292645A2 (en) Small Streptococcus pyogenes antigens and their use
US6716432B1 (en) Pneumolysin mutants and pneumococcal vaccines made therefrom
SG192060A1 (en) Vaccines and compositions against streptococcus pneumoniae
WO2014018904A1 (en) Fused antigen vaccines and compositions against streptococcus pneumoniae
KR0180559B1 (ko) 스트렙토코커스 b군에 대한 백신 접합체
US20150079132A1 (en) Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
AU2013209513B2 (en) Fused antigen vaccines and compositions against Streptococcus pneumoniae
Paton New pneumococcal vaccines: basic science developments
RU2701733C1 (ru) Живая вакцина на основе штамма пробиотиков ENTEROCOCCUS FAECIUM L3 для профилактики инфекции, вызванной STREPTOCOCCUS PNEUMONIE
Paton et al. Protein vaccines
HK1074005B (en) Compositions and methods for treating or preventing pneumococcal infection
AU722078B2 (en) Conjugate vaccine against group B Streptococcus
Paton et al. Streptococcus pneumoniae vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20081217